July 24, 2025
AstraZeneca’s Self-Administered Myasthenia Gravis Drug Gefurulimab Clears Phase 3 Trial
AstraZeneca; gefurulimab; myasthenia gravis; self-administered drug; Phase 3 trial; PREVAIL trial; C5 inhibitor; autoimmune disease; clinical trial; Alexion acquisition
RFK Jr. Approves ACIP Recommendation to Remove Thimerosal from U.S. Flu Vaccines
RFK Jr.; Thimerosal; ACIP; Vaccine Safety
LEO Pharma Scores FDA Approval for Anzupgo as First Treatment for Chronic Hand Eczema
LEO Pharma; Anzupgo; delgocitinib; FDA approval; chronic hand eczema; pan-JAK inhibitor; moderate-to-severe CHE; topical treatment
FDA Delays Blenrep Decision, Challenging GSK’s Multiple Myeloma Comeback Plans
FDA delay; Blenrep; GSK; multiple myeloma; regulatory hurdles; ocular toxicity; PDUFA; oncology; relapsed/refractory
Flagship’s Most-Funded Startups, Generate and Tessera, Announce Layoffs in 2025
Flagship Pioneering; startups; Generate:Biomedicines; Tessera; layoffs; biotech; 2025
Apnimed Advances FDA Filing after Second Pivotal Win for Oral Sleep Apnoea Drug
Apnimed; AD109; obstructive sleep apnea; OSA; oral drug; phase 3 trial; LunAIRo; SynAIRgy; FDA submission; clinical trial; aroxybutynin; atomoxetine